Carobbio, Alessandra
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.506
NA - Nord America 4.960
EU - Europa 1.833
SA - Sud America 706
Continente sconosciuto - Info sul continente non disponibili 158
AF - Africa 84
OC - Oceania 12
Totale 13.259
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.798
CN - Cina 2.237
SG - Singapore 1.386
BR - Brasile 531
HK - Hong Kong 519
IT - Italia 487
VN - Vietnam 460
KR - Corea 425
GB - Regno Unito 302
FI - Finlandia 298
RU - Federazione Russa 163
BD - Bangladesh 148
FR - Francia 131
SE - Svezia 124
AR - Argentina 84
ID - Indonesia 82
CA - Canada 76
DE - Germania 64
IN - India 59
NL - Olanda 56
LT - Lituania 43
MX - Messico 43
PK - Pakistan 37
JP - Giappone 30
ZA - Sudafrica 30
ES - Italia 26
PL - Polonia 25
EC - Ecuador 23
IQ - Iraq 23
AT - Austria 22
CO - Colombia 22
UA - Ucraina 20
JM - Giamaica 15
CL - Cile 12
CR - Costa Rica 12
MA - Marocco 12
UZ - Uzbekistan 11
CZ - Repubblica Ceca 10
PY - Paraguay 10
CH - Svizzera 9
GR - Grecia 9
TN - Tunisia 9
NP - Nepal 8
AU - Australia 7
PE - Perù 7
SA - Arabia Saudita 7
TR - Turchia 7
ET - Etiopia 6
IE - Irlanda 6
KE - Kenya 6
PH - Filippine 6
VE - Venezuela 6
BO - Bolivia 5
HR - Croazia 5
JO - Giordania 5
MY - Malesia 5
RO - Romania 5
UY - Uruguay 5
AZ - Azerbaigian 4
BA - Bosnia-Erzegovina 4
BG - Bulgaria 4
DZ - Algeria 4
EG - Egitto 4
GE - Georgia 4
IL - Israele 4
KZ - Kazakistan 4
SI - Slovenia 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
DO - Repubblica Dominicana 3
GT - Guatemala 3
HN - Honduras 3
HU - Ungheria 3
KG - Kirghizistan 3
KH - Cambogia 3
LB - Libano 3
NZ - Nuova Zelanda 3
OM - Oman 3
QA - Qatar 3
RS - Serbia 3
AM - Armenia 2
BH - Bahrain 2
MD - Moldavia 2
NG - Nigeria 2
NO - Norvegia 2
PT - Portogallo 2
SC - Seychelles 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
AO - Angola 1
BB - Barbados 1
BS - Bahamas 1
BY - Bielorussia 1
CG - Congo 1
CI - Costa d'Avorio 1
DK - Danimarca 1
DM - Dominica 1
GY - Guiana 1
HT - Haiti 1
IR - Iran 1
Totale 13.084
Salva come PNG Salva come JPEG
Città #
Hefei 1.544
Santa Clara 1.334
Singapore 768
San Jose 560
Ashburn 524
Hong Kong 513
Seoul 423
Council Bluffs 335
Helsinki 283
London 240
Ho Chi Minh City 184
Chicago 125
Milan 117
The Dalles 110
Los Angeles 98
Hanoi 95
Kent 91
Lauterbourg 90
Beijing 87
Moscow 64
New York 60
Jakarta 58
Buffalo 52
Boardman 51
Salt Lake City 47
Redondo Beach 46
São Paulo 42
Piscataway 40
Dallas 39
Shanghai 39
North Bergen 38
Phoenix 38
Amsterdam 29
Secaucus 28
Brooklyn 25
Da Nang 25
Nuremberg 23
Rome 23
Atlanta 22
Elk Grove Village 21
Rio de Janeiro 21
Denver 20
Plano 20
Warsaw 19
Tokyo 18
Frankfurt am Main 17
Newark 17
Tampa 17
Curitiba 16
Johannesburg 16
Haiphong 15
Karachi 15
Chennai 14
Miano 14
Montreal 14
Ealing 13
Tianjin 13
Boston 12
Brasília 12
Florence 12
Guangzhou 12
Guayaquil 12
Houston 12
Miami 12
Orem 12
Toronto 12
Campinas 11
Clifton 11
Dhaka 11
Lappeenranta 11
Mexico City 11
Vienna 11
Baghdad 10
Las Vegas 10
Padua 10
Tashkent 10
Turin 10
Assago 8
Bari 8
Biên Hòa 8
Chengdu 8
Dulles 8
Fort Lauderdale 8
Hillsboro 8
Kingston 8
Lahore 8
Ninh Bình 8
Paris 8
Pinole 8
Salvador 8
San Francisco 8
Seattle 8
Wilmington 8
Baton Rouge 7
Belo Horizonte 7
Buenos Aires 7
Cape Town 7
Columbus 7
Maceió 7
Porto Alegre 7
Totale 9.011
Salva come PNG Salva come JPEG
Nome #
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis) 234
Masked polycythemia vera (mPV): results of an international study 216
Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer 201
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial 197
The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients 184
A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms 182
Association between cuffed tracheal tube use and reduced ventilator-associated pneumonia and conditions after elective cardiac surgery in infants and young children 180
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome 175
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes 171
A globally applicable “triple A” risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count 162
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19 159
Acute and Subacute Outcome Predictors in Moderate and Severe Traumatic Brain Injury: A Retrospective Monocentric Study 158
Long-term follow-up of recovered MPN patients with COVID-19 155
A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment 149
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 149
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera 145
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera 144
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study 141
A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis 140
Adherence of ticagrelOr in real world patients with aCute coronary syndrome: The AD-HOC study 140
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists 139
A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study 138
A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes 137
Age-stratified analysis reveals arterial thrombosis as a predictor for gender-related second cancers in myeloproliferative neoplasms: a case-control study 137
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer. A case-control study 135
The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis 134
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib 134
Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation 132
Induction of Remission With Exclusive Enteral Nutrition in Children With Crohn’s Disease: Determinants of Higher Adherence and Response 131
Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status 129
Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis 128
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia 127
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients 126
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study 123
JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera 122
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera 122
Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19 121
Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts 121
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia 120
Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis 119
Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin 119
Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria 118
Thrombosis in primary myelofibrosis: incidence and risk factors 117
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis 117
Are the available data sufficient to suggest cytoreductive agents for patients with CHIP and stroke? 115
ASXL1 mutations in primary and secondary myelofibrosis 115
Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia 113
No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials 110
The impact of a standardized perioperative management on hospital mortality after the Norwood procedure in a low volume center: results and perspectives 110
One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity 109
The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600 109
Masked polycythemia vera diagnosed according to WHO and BCSH classification 109
Risk factors for intubation in severe bronchiolitis: a useful tool to decide on an early intensive respiratory support 109
Three-month mortality in permanently bedridden medical non-oncologic patients. The BECLAP study (permanently BEdridden, creatinine CLearance, albumin, previous hospital admissions study) 109
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score 108
Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis 107
Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID‐19 105
Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status 105
Innovative haematological parameters for early diagnosis of sepsis in adult patients admitted in intensive care unit 105
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3 105
Pre-Transplant Alpha-Fetoprotein > 25.5 and Its Dynamic on Waitlist Are Predictors of HCC Recurrence after Liver Transplantation for Patients Meeting Milan Criteria 104
Splanchnic Vein Thromboses associated with Myeloproliferative Neoplasms: an international, retrospective study on 518 cases 103
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients 103
Cerebral venous thrombosis and myeloproliferative neoplasms: A three‐center study of 74 consecutive cases 103
Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial 102
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study 102
Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera 101
Full-right-full-left split liver transplantation: the retrospective analysis of an early multicenter experience including graft sharing 100
Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach 100
Echocardiographic outflow pump ramp test in centrifugal-flow left ventricular assist device 100
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients 100
Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy 100
Generating signals of drug-adverse effects from prescription databases and application to the risk of arrhythmia associated with antibacterials 99
ACE inhibitors and cytoreductive therapy in polycythemia vera 99
Neutrophil-to-lymphocyte ratio as a prognostic indicator of mortality in Polycythemia Vera: insights from a prospective cohort analysis 98
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study 98
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology 98
Neutrophil/lymphocyte ratio identifies low-risk polycythaemia vera patients for early Ropeginterferon alfa-2b therapy 97
Predicting the occurrence of embolic events: an analysis of 1456 episodes of infective endocarditis from the Italian Study on Endocarditis (SEI) 97
Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification 97
The effect of arterial hypertension on thrombosis in low-risk polycythemia vera 94
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma 94
Second versus first wave of COVID-19 in patients with MPN 93
Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis 93
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F) 93
Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review 92
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients 92
Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases 91
Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment 90
Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients 89
CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis 89
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria 88
PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics 88
Second cancers in MPN : Survival analysis from an international study 87
Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients 87
Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis 86
Leukocytosis and thrombosis in polycythemia vera: can clinical trials settle the debate? 85
Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis 85
Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma 84
Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data 84
Totale 11.956
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.535
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.535
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024415 0 0 0 0 0 0 0 210 37 17 64 87
2024/20253.911 40 25 28 270 745 769 220 47 405 144 592 626
2025/20268.140 703 728 1.034 1.089 391 423 988 291 845 602 540 506
2026/2027793 418 375 0 0 0 0 0 0 0 0 0 0
Totale 13.259